OSCO serves as the hub for oncology-related news and advances in Oklahoma. Our organization is made up of clinics and healthcare professionals working together to safeguard the rights of patients and to maintain high medical and ethical standards in the industry.
Melphalan Flufenamide (PEPAXTO®) is now included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma Version 6.2021 – April 12, 2021 Category 2A1 Definitions for National Comprehensive Cancer Network® (NCCN®) Categories: Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. For more […]
Read More...Multiple Myeloma is the 2nd most common blood cancer (Cancer Facts & Figures 2020), accounting for about 1.8% of all cancers (SEER Cancer Stat Facts: Myeloma) and is the leading hematologic cancer in African Americans (Pierre and Williams. Clin J Oncol Nursing. 2020;24:439-443). An estimated 32,000 patients were diagnosed with multiple myeloma in the United States in […]
Read More...On April 19, Oklahoma Governor Kevin Stitt (R) signed co-pay accumulator ban bill HB 2678 into law. This measure requires Pharmacy Benefit Managers (PBMs) to include any amount paid by an enrollee, or on behalf of an enrollee, when calculating the enrollee’s out of pocket maximum, copay, coinsurance, deductible, or cost sharing requirement. The Oklahoma […]
Read More...Join OSCO for the Official Best of San Antonio Breast Cancer Symposium® to be presented virtually. This conference is designed to provide state-of-the art information on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease.
Your company can sponsor OSCO and the work we do by becoming a corporate member today! For more information or to sign up, contact Kathy Musson, OSCO Executive Director at [email protected] or by phone at 405-850-8334.
The Oklahoma Society of Clinical Oncology (OSCO) is Oklahoma’s only professional organization that represents all those in oncology. Our membership works to advance the sciences of hematology and oncology and its sub-specialties, and to improve services to the public by studying the socio-economic aspects of the practice of our members.
